Clinical pharmacokinetics of buffered propranolol sublingual tablet (promptol™) - Application of a new "physiologically based" model to assess absorption and disposition

AAPS Journal

Volumn 15, Issue 3, 2013, Pages 787-796

  Wang, Yanfeng ^a,b   Wang, Zhijun ^c   Zuo, Zhong ^b   Tomlinson, Brian ^a   Lee, Benjamin T K ^b   Bolger, Michael B ^d   Chow, Moses S S ^c  

^a Prince of Wales Hospital   (Hong Kong)

^b Hong Kong Science Park   (Hong Kong)

^c WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^d Simulations Plus Inc   (United States)

Author keywords

ACAT; buffered; pharmacokinetics; propranolol; sublingual

Indexed keywords

PROMPTOL; PROPRANOLOL; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; MALE; MUCOSA INFLAMMATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MOUTH MUCOSA; PROPRANOLOL; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84879793290     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9479-1     Document Type: Article

References (29)

1. Frishman WH. β-Adrenoceptor antagonists: new drugs and new indications. New Engl J Med. 1981;305(9):500-6. doi: 10.1056/ NEJM198108273050907.
2. Angrini M, Leslie JC, Shephard RA. Effects of propranolol, buspirone, pCPA, reserpine, and chlordiazepoxide on open-field behavior. Pharmacol Biochem Behav. 1998;59(2):387-97. doi: 10.1016/s0091-3057(97)00457-7.
3. Fourneret P, Desombre H, de Villard R, Revol O. Interest of propranolol in the treatment of school refusal anxiety: about three clinical observations. Encephale. 2001;27(6):578-84.
4. Gruber RP, Roberts C, Schooler W, Pitman RK. Preventing postsurgical dissatisfaction syndrome after rhinoplasty with propranolol: a pilot study. Plast Reconstr Surg. 2009;123(3):1072-8. doi: 10.1097/PRS.0b013e318199f63f.
5. Mazzuero G, Galdangelo F, Zotti AM, Bertolotti G, Tavazzi L. Effects of propranolol, atenolol, and chlordesmethyldiazepam on response to mental stress in patients with recent myocardial infarction. Clin Cardiol. 1987;10(6):293-302.
6. Mealy K, Ngeh N, Gillen P, Fitzpatrick G, Keane FB, Tanner A. Propranolol reduces the anxiety associated with day case surgery. Eur J Surg. 1996;162(1):11-4.
7. Taylor F, Cahill L. Propranolol for reemergent posttraumatic stress disorder following an event of retraumatization: a case study. J Trauma Stress. 2002;15(5):433-7. doi: 10.1023/a:1020145610914.
8. Vaiva G, Ducrocq F, Jezequel K, Averland B, Lestavel P, Brunet A, et al. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry. 2003;54(9):947-9. doi: 10.1016/s0006-3223(03)00412-8.
9. Mathias NR, Hussain MA. Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J Pharm Sci. 2010;99(1):1-20. doi: 10.1002/jps.21793.
10. Squier CA, Hall BK. In-vitro permeability of porcine oral mucosa after epithelial separation, stripping and hydration. Arch Oral Biol. 1985;30(6):485-91.
11. Duchateau GSMJE, Zuidema J, Merkus FWHM. Bioavailability of propranolol after oral, sublingual, and intranasal administration. Pharm Res. 1986;3(2):108-11.
12. Chow M, Zuo JZ, Wang Y. Method of enhancing absorptions of transmucosal administration formulations. USA patent, 2008: US7329416.
13. Wang Y, Zuo Z, Chen X, Tomlinson B, Chow MSS. Improving sublingual delivery of weak base compounds using pHmax concept: application to propranolol. Eur J Pharm Sci. 2010;39(4):272-8. doi: 10.1016/j.ejps.2009.12.011.
14. Huang W, Lee SL, Yu LX. Mechanistic approaches to predicting oral drug absorption. AAPS J. 2009;11(2):217-24. doi: 10.1208/s12248-009-9098-z.
15. Lukacova V, Woltosz W, Bolger M. Prediction of modified release pharmacokinetics and pharmacodynamics from < b > in vitro immediate release, and intravenous data. AAPS J. 2009;11(2):323-34. doi: 10.1208/s12248-009-9107-2.
16. Bolger M, Lukacova V, Woltosz W. Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine. AAPS J. 2009;11(2):353-63. doi: 10.1208/s12248-009-9111-6.
17. Olanoff LS, Walle T, Cowart TD, Walle UK, Oexmann MJ, Conradi EC. Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. Clin Pharmacol Ther. 1986;40(4):408-14.
18. Shargel L, Wu-Pong S, Yu ABC. Applied biopharmaceutics & pharmacokinetics, 5th edn. New York: McGraw-Hill Medical Publishing Division; 2004.
19. Boxenbaum HG, Riegelman S, Elashoff RM. Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm. 1974;2(2):123-48.
20. Kates RE. Absorption kinetics of sublingually administered propranolol. J Med. 1977;8(6):393-402.
21. Henry JA, Ohashi K, Wadsworth J, Turner P. Drug recovery following buccal absorption of propranolol. Br J Clin Pharmacol. 1980;10(1):61-5.
22. Gomeni R, Bianchetti G, Sega R, Morselli PL. Pharmacokinetics of propranolol in normal healthy volunteers. J Pharmacokinet Biopharm. 1977;5(3):183-92.
23. Bruce TJ, Saeed SA. Social anxiety disorder: a common, underrecognized mental disorder. Am Fam Physician. 1999;60(8):2311-20. 22.
24. Pine M, Favrot L, Smith S, McDonald K, Chidsey CA. Correlation of plasma propranolol concentration with therapeutic response in patients with angina pectoris. Circulation. 1975;52(5):886-93. doi: 10.1161/01.cir.52.5.886.
25. AHFS Drug Information. Bethesda, MD Authority of the Board of the American Society of Health-system Pharmacists; American Hospital Formulary Service; 2012.
26. Julius S, Pascual AV, London R. Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation. 1971;44(3):413-8. doi: 10.1161/01.cir.44.3.413.
27. Weiss YA, Safar ME, Chevillard C, Frydman A, Simon A, Lemaire P, et al. Comparison of the pharmacokinetics of intravenous dl-propranolol in borderline and permanent hypertension. Eur J Clin Pharmacol. 1976;10(6):387-93.
28. Mansur Ade P, Ramires JA, Avakian SD, de Paula RS, Pileggi F. [Comparison of the effects of diazepam, nifedipine, propranolol and a combination of nifedipine and propranolol, by sublingual administration, in patients with hypertensive crisis]. Arq Bras Cardiol. 1991;57(4):313-7.
29. Johnston GD. Dose-response relationships with antihypertensive drugs. Pharmacol Therapeut. 1992;55(1):53-93. doi: 10.1016/0163-7258(92)90029-y.